Empagliflozin CV Outcomes Data: Is Sum Of The Parts Greater Than Whole?
This article was originally published in The Pink Sheet Daily
Boehringer and Lilly focus on CV death, are not seeking broader indication for Jardiance based on less impressive primary composite endpoint results.
You may also be interested in...
US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.
Review documents do not always reflect whether PED was considered as part of an application, and stakeholders cannot easily determine how such data are used in the agency’s regulatory decision-making, an independent consultant review found.